The cleanest GHRP — price comparison across top research peptide suppliers
Last updated: April 2026 | Prices scraped across 5 suppliers | Swiss Chems 2mg & Spectrum/STL 5mg confirmed
Prices below reflect April 2026 scraper data. Swiss Chems 2mg and Spectrum/STL 5mg pricing is confirmed scraped. Remaining supplier estimates are based on current market ranges. Always verify directly with each supplier before purchasing.
| Supplier | Price (2mg) | Per-mg Cost | Notes |
|---|---|---|---|
| Swiss Chems Best Value | $17.95 (on sale, was $21.95) | $8.98/mg | Confirmed scraped Apr 2026 · crypto discount ~10% |
| Spectrum Peptides | ~$18–$20 | ~$9–$10/mg | Est. — 5mg confirmed at $35; 2mg not directly scraped |
| Behemoth Labz | ~$19–$22 | ~$9.50–$11/mg | Est. — bundle deals often available with CJC-1295 |
| STL Peptides | ~$22–$25 | ~$11–$12.50/mg | Est. — 5mg confirmed at $54.99; 2mg similar ratio |
| Peptide Lab | ~$20–$25 | ~$10–$12.50/mg | Est. — 10mg confirmed at $100 ($10/mg); AUD pricing |
| Supplier | Price (5mg) | Per-mg Cost | vs. 2mg per-mg |
|---|---|---|---|
| Spectrum Peptides Best Value | $35.00 | $7.00/mg | Confirmed scraped Apr 2026 · US domestic |
| Swiss Chems | ~$29–$35 | ~$5.99–$7/mg | Est. — 2mg confirmed; 5mg not directly scraped this run |
| Behemoth Labz | ~$40–$45 | ~$8–$9/mg | Est. — bundle deals often available with CJC-1295 |
| STL Peptides | $54.99 | $11.00/mg | Confirmed scraped Apr 2026 · US domestic |
| Peptide Lab | ~$50–$60 | ~$10–$12/mg | Est. — 10mg confirmed at $100 ($10/mg); ratio applied |
Lowest confirmed 2mg price: Swiss Chems $17.95 on sale (was $21.95).
Best confirmed 5mg value: Spectrum Peptides $35.00 ($7.00/mg) — scraped April 2026.
Stack savings: Behemoth Labz bundle deals frequently include Ipamorelin + CJC-1295 together at better combined pricing than buying separately.
Also available: Peptide Lab carries a 10mg vial at $100 ($10/mg) — good for longer protocols without multiple reorders.
| Protocol | Duration | Dose / Frequency | Total mg | Est. Cost (Spectrum 5mg @ $35) |
|---|---|---|---|---|
| Low dose, bedtime only | 30 days | 100mcg × 1/day | 3mg | ~$35 (1× 5mg vial) |
| Standard twice-daily | 30 days | 200mcg × 2/day | 12mg | ~$105 (3× 5mg vials) |
| Three-times daily | 30 days | 200mcg × 3/day | 18mg | ~$140 (4× 5mg vials) |
| With CJC-1295 stack | 30 days | 100mcg Ipa + 100mcg CJC, 2/day | 6mg Ipa + 6mg CJC | ~$80–100 combined |
Ipamorelin (Aib-His-D-2Nal-D-Phe-Lys-NH2) is a synthetic pentapeptide developed in the late 1990s by Novo Nordisk as part of a program to identify selective growth hormone secretagogues. It emerged from the same research lineage as GHRP-6 and GHRP-2, but with a critical refinement: high selectivity for the GHS-R1a receptor with minimal off-target activity.
Where GHRP-6 was potent but caused significant appetite stimulation and hunger pangs, and GHRP-2 raised cortisol and prolactin at higher doses, Ipamorelin produces a clean GH pulse with none of these side effects. This selectivity profile made it one of the most studied GHRPs for longer-duration research protocols.
Binds the ghrelin receptor (GHS-R1a) in the pituitary with high selectivity. Triggers GH release without meaningfully activating other receptor subtypes — the key to its clean profile.
Produces a sharp, defined GH pulse lasting ~2–3 hours. This mimics the natural pattern of youthful GH secretion rather than creating sustained elevated GH levels.
Unlike GHRP-2, GHRP-6, and Hexarelin, Ipamorelin does not significantly elevate cortisol or prolactin even at high doses in research models. This makes it suitable for long-duration protocols.
GHS-R1a receptor desensitization with Ipamorelin is much slower than with Hexarelin. Months of continuous use maintain responsiveness better than most other GHRPs — a key advantage for longevity and GH restoration protocols.
Ipamorelin sits in a specific niche within the GHRP category: moderate GH potency with the best selectivity and tolerability profile of any studied GHRP.
| Property | Ipamorelin | Hexarelin | GHRP-2 | GHRP-6 |
|---|---|---|---|---|
| GH Potency | ★★★☆☆ Moderate | ★★★★★ Highest | ★★★★☆ | ★★★☆☆ |
| Selectivity (GH only) | ★★★★★ Excellent | ★★★☆☆ Multi-receptor | ★★★☆☆ | ★★☆☆☆ |
| Cortisol Rise | ✅ None | ⚠️ Yes (dose-dependent) | ⚠️ Mild | ✅ Minimal |
| Appetite Stimulation | ✅ Minimal | ⚠️ Mild–Moderate | ⚠️ Moderate | ❌ Strong |
| Desensitization Speed | Slow (best) | Fast | Moderate | Moderate |
| Long Protocol Suitability | ✅ Excellent | ⚠️ Cycle required | ⚠️ Moderate | ⚠️ Moderate |
| Typical 2mg Price | ~$15–$25 | ~$15–$25 | ~$10–$18 | ~$10–$18 |
The combination of Ipamorelin (a GHRP) and CJC-1295 without DAC (a GHRH analogue) is the most widely studied GH restoration stack in the research peptide field. The two peptides work through completely different receptor pathways and are synergistic — producing significantly more GH than either produces alone.
For full CJC-1295 pricing and the DAC vs. no-DAC comparison, see our CJC-1295 price guide.
Spectrum's 5mg Ipamorelin was scraped at $35.00 ($7.00/mg) in April 2026. This is the best confirmed 5mg price we found across all scraped suppliers. Consistent availability, US domestic shipping, COA available.
Swiss Chems 2mg was scraped at $17.95 (on sale from $21.95) in April 2026. Their 5mg pricing was not captured in this scraper run, but typically offers competitive per-mg value. Accepts cards and crypto — crypto discount of ~10% lowers effective cost further.
Behemoth Labz periodically runs bundles that include Ipamorelin + CJC-1295 together at a discount. If you're planning the full stack, check their current bundle pricing before buying separately.
Peptide Lab offers Ipamorelin in a 10mg vial at $100 ($10.00/mg) — confirmed scraped April 2026. Higher per-mg cost than Spectrum's 5mg, but fewer reorders needed for longer protocols. Australian supplier with AUD/USD pricing variation.
We'll email you when Ipamorelin drops below your target price at any supplier.
Ipamorelin's selectivity means it binds GHS-R1a strongly but has minimal affinity for other receptor targets. GHRP-6 activates ghrelin receptors in the gut (causing hunger) in addition to the pituitary. GHRP-2 and Hexarelin activate receptors related to cortisol and prolactin release. Ipamorelin's structural design — particularly the D-2-naphthylalanine at position 3 — confers high selectivity for the pituitary GHS-R1a receptor while avoiding these off-target receptor activations. The result is that the GH pulse is relatively "clean" — you get the GH release without the appetite stimulation, hunger pangs, cortisol spike, or prolactin elevation seen with less selective GHRPs.
Research consistently shows the combination with a GHRH analogue (CJC-1295 without DAC, or Sermorelin) produces substantially larger GH pulses than Ipamorelin alone. The synergistic effect is well-documented — the GHRH component primes the pituitary's somatotroph cells while Ipamorelin triggers the release. For body composition or GH restoration research goals, the stack is generally more relevant than Ipamorelin alone. Ipamorelin as a standalone is sometimes used when researchers want to avoid the longer-acting kinetics of CJC-1295 and maintain more precise control over GH pulse timing.
For a 12-week protocol, Ipamorelin is generally the preferred choice due to its much slower desensitization rate. Hexarelin's GHS-R1a receptor down-regulation becomes significant within 4–8 weeks of continuous use, requiring cycling to maintain efficacy. Ipamorelin maintains receptor sensitivity over longer periods, making it more suitable for continuous 12-week research. The tradeoff is that Hexarelin produces a larger GH pulse per dose — but if that pulse diminishes significantly by week 6 due to desensitization, the theoretical advantage disappears. Ipamorelin's more consistent response over time typically outweighs Hexarelin's initial potency advantage in extended protocols.
Yes. Ipamorelin is prohibited by WADA under the S2 category "Peptide Hormones, Growth Factors, Related Substances and Mimetics" — specifically as a growth hormone secretagogue. It is prohibited both in-competition and out-of-competition for athletes in WADA-governed sports. This applies regardless of how it is used or what dose is taken. Athletes subject to anti-doping testing should avoid Ipamorelin and all other GH secretagogues.
Some research protocols rotate between GHRPs — for example, using Ipamorelin continuously and substituting Hexarelin for short high-intensity cycles, then returning to Ipamorelin during the off period. The rationale is to leverage Hexarelin's higher GH pulse amplitude periodically while using Ipamorelin's superior sustained-use profile for the majority of the protocol. This approach is speculative in terms of optimal design but is mechanistically plausible given the different desensitization kinetics of the two peptides.